| Serial Number | 88912457 |
| Word Mark | PREVADDUCT |
| Filing Date | Tuesday, May 12, 2020 |
| Status | 606 - ABANDONED - NO STATEMENT OF USE FILED |
| Status Date | Monday, December 18, 2023 |
| Registration Number | 0000000 |
| Registration Date | NOT AVAILABLE |
| Mark Drawing | 4000 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form |
| Published for Opposition Date | Tuesday, September 15, 2020 |
| Goods and Services | Dietary and nutritional supplements; Digestives for pharmaceutical purposes; Pharmaceutical products for treating respiratory diseases and asthma; Pharmaceutical agents affecting digestive organs; Pharmaceutical agents affecting metabolism; Pharmaceutical agents affecting peripheral nervous system; Pharmaceutical agents affecting sensory organs; Pharmaceutical agents for epidermis; Pharmaceutical anti-allergic preparations and substances; Pharmaceutical preparation for skin care; Pharmaceutical preparations acting on the central nervous system; Pharmaceutical preparations and substances for the treatment of damaged skin and tissue; Pharmaceutical preparations and substances for the treatment of gastro-intestinal diseases; Pharmaceutical preparations and substances for the treatment of infectious diseases, blood disorders, pain, inflammation, sepsis, alopecia, obesity and cognitive disorders; Pharmaceutical preparations and substances for the treatment of psychiatric diseases and disorders; Pharmaceutical preparations and substances for the treatment of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric and immune system related diseases and disorders; Pharmaceutical preparations for inhalation for the treatment of pulmonary hypertension; Pharmaceutical preparations for the prevention of inflammation; Pharmaceutical preparations for the prevention of inflammatory diseases; Pharmaceutical preparations for the treatment and prevention of oxidative damage; Pharmaceutical preparations for the treatment and prevention of chronic inflammation; Pharmaceutical preparations for the treatment of eye diseases and conditions; Pharmaceutical preparations for the treatment of hormonal disorders; Pharmaceutical preparations for the treatment of immune system related diseases and disorders; Pharmaceutical preparations for the treatment of infectious diseases; Pharmaceutical preparations for the treatment of musculo-skeletal disorders; Pharmaceutical preparations for the treatment of chronic inflammation; Pharmaceutical preparations for the treatment of oxidative damage; Pharmaceutical preparations for the treatment of isoketal activity diseases and conditions; Pharmaceutical preparations for the treatment of musculoskeletal, cardiovascular, cardiopulmonary, and immune system related diseases and disorders; Pharmaceutical preparations for treating allergies; Pharmaceutical preparations for treating asthma; Pharmaceutical preparations for treating chemical imbalances; Pharmaceutical preparations for treating diabetes; Pharmaceutical preparations for treating hypertension; Pharmaceutical preparations for treating skin disorders; Pharmaceutical preparations for inflammation; Pharmaceutical preparations, namely, anticoagulants; Pharmaceutical preparations, namely, antidepressants; Pharmaceutical preparations, namely, antivirals; Pharmaceutical products and preparations against dry skin caused by pregnancy; Pharmaceutical products and preparations for pregnancy blemishes; Pharmaceutical products for ophthalmological use; Pharmaceutical products for the prevention and treatment of cancer; Pharmaceutical products for the treatment of bone diseases; Pharmaceutical products for the treatment of cancer; Pharmaceutical products for the treatment of joint disease; Pharmaceutical products for treating respiratory diseases; Anti-inflammatory preparations; Chemical preparations for pharmaceutical or medical purposes, namely, for oxidative damage, isoketal activity and chronic inflammation; Chemical preparations for pharmaceutical or medical purposes, namely, for diseases resulting from oxidative damage, isoketal activity or inflammation; Food supplements, namely, anti-oxidants; Medical preparations for the treatment of oxidative damage, isoketal activity and chronic inflammation; Medicinal preparations for inflammation; Pharmaceutical products and preparations to prevent swelling in the legs; Preparation for the relief of pain |
| International Class | 005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides. |
| US Class Codes | 006, 018, 044, 046, 051, 052 |
| Class Status Code | 6 - Active |
| Class Status Date | Tuesday, May 26, 2020 |
| Primary Code | 005 |
| First Use Anywhere Date | NOT AVAILABLE |
| First Use In Commerce Date | NOT AVAILABLE |
| Party Name | Adduct Pharmaceutical, Inc. |
| Party Type | 20 - Owner at Publication |
| Legal Entity Type | 03 - Corporation |
| Address | Ames, IA 50010 |
| Party Name | Adduct Pharmaceutical, Inc. |
| Party Type | 10 - Original Applicant |
| Legal Entity Type | 03 - Corporation |
| Address | Ames, IA 50010 |
| Event Date | Event Description |
| Monday, December 18, 2023 | ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED |
| Monday, December 18, 2023 | ABANDONMENT - NO USE STATEMENT FILED |
| Friday, May 12, 2023 | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED |
| Thursday, May 11, 2023 | SOU EXTENSION 5 GRANTED |
| Sunday, May 7, 2023 | SOU EXTENSION 5 FILED |
| Thursday, May 11, 2023 | CASE ASSIGNED TO INTENT TO USE PARALEGAL |
| Sunday, May 7, 2023 | SOU TEAS EXTENSION RECEIVED |
| Saturday, November 12, 2022 | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED |
| Thursday, November 10, 2022 | SOU EXTENSION 4 GRANTED |
| Thursday, November 10, 2022 | SOU EXTENSION 4 FILED |
| Thursday, November 10, 2022 | SOU TEAS EXTENSION RECEIVED |
| Tuesday, May 10, 2022 | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED |
| Sunday, May 8, 2022 | SOU EXTENSION 3 GRANTED |
| Sunday, May 8, 2022 | SOU EXTENSION 3 FILED |
| Sunday, May 8, 2022 | SOU TEAS EXTENSION RECEIVED |
| Tuesday, November 9, 2021 | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED |
| Friday, November 5, 2021 | SOU EXTENSION 2 GRANTED |
| Friday, November 5, 2021 | SOU EXTENSION 2 FILED |
| Friday, November 5, 2021 | SOU TEAS EXTENSION RECEIVED |
| Wednesday, May 12, 2021 | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED |
| Monday, May 10, 2021 | SOU EXTENSION 1 GRANTED |
| Monday, May 10, 2021 | SOU EXTENSION 1 FILED |
| Monday, May 10, 2021 | SOU TEAS EXTENSION RECEIVED |
| Tuesday, November 10, 2020 | NOA E-MAILED - SOU REQUIRED FROM APPLICANT |
| Tuesday, September 15, 2020 | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED |
| Tuesday, September 15, 2020 | PUBLISHED FOR OPPOSITION |
| Wednesday, August 26, 2020 | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED |
| Tuesday, August 11, 2020 | APPROVED FOR PUB - PRINCIPAL REGISTER |
| Sunday, August 9, 2020 | ASSIGNED TO EXAMINER |
| Tuesday, May 26, 2020 | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED |
| Friday, May 15, 2020 | NEW APPLICATION ENTERED |